Background-Pregnant women with a mechanical heart valve (MHV) are at a heightened risk of
Introduction
The true extent of the adverse impact of structural heart disease on the outcome of pregnancy has become clearer over the last decade [1] [2] [3] . The marked hemodynamic changes and the hypercoagulable state in pregnancy increase the risk of complications in patients with cardiovascular disease and fetal development can be compromised by a failure of cardiac function or the need for cardiac medication. This is particularly true of women with a mechanical heart valve prosthesis (MHV), where the hypercoagulable state makes the maintenance of effective anticoagulation challenging 4, 5 . More than 200,000 aortic valve replacements are performed each year worldwide 6 , let alone replacements of heart valves in other positions. But the exact percentage of women of reproductive age having a mechanical valve is unknown.
Indeed, having a MHV has been shown to be a predictor of adverse outcome of pregnancy 2, 7 , but studies are scarce and numbers are small.
In women at reproductive age with a MHV, the need to maintain adequate anticoagulation to prevent mechanical valve thrombosis (MVT) has to be balanced against the risks of teratogenicity, fetotoxicity and bleeding. Current guidelines recommend Vitamin K Antagonists (VKA) in the first trimester for the highest risk patients, while in the other patients dose adjusted low-molecular-weight-heparin (LMWH), unfractionated heparin (UFH) or VKA can be used 8, 9 . Thereafter, a VKA is recommended until 36 weeks, when it should be replaced with (low-molecular-weight) heparin mainly to prevent fetal intracranial hemorrhage during vaginal delivery. These guidelines however, are based on weak scientific evidence (level C) and the optimal anticoagulation regime to use in pregnancy remains very uncertain_ENREF_9 2 . We have carried out a prospective observational study of a large number of pregnancies in MHV patients in a broad range of clinical practices from developed and emerging countries. We he exact percentage of women of reproductive age having a mechanical valve is un un unkn kn know ow own n. n.
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Methods

Study design
The Registry of Pregnancy and Cardiac Disease (ROPAC) began in January 2008 as part of the Euro Heart Survey, which since 2009 is called EURObservational Research Programme (EORP)
of the European Society of Cardiology. Details of the study design were previously published 3 .
Pregnant women with structural heart or aortic disease were prospectively enrolled. When a center joined the Registry, they were allowed to include patients up to 6 months retrospectively.
If required, ethical approval or Institutional Review Board approval was obtained (e.g. The
Netherlands, Germany, USA, Canada, and Belgium) and subjects gave written informed consent.
However, in some countries the procedure to obtain ethical approval was waived because of the anonymized and untraceable nature of the data.
The first term of data collection ran until June 2011 and reports were published on these data 3, 10 . The current study reports on the outcome and complications of pregnancy in women included in the Registry up to April 1 st 2014, who had a MHV compared to the outcome of women with a THV and of women with structural heart disease but no prosthetic heart valve (NoPHV). To put the results in perspective, outcome of the normal pregnant population is also reported based on available literature 3, 11 .
Clinical data
Baseline characteristics included maternal age, general cardiovascular risk factors, major nonPregnant women with structural heart or aortic disease were prospectively enrolled ed ed. . . Wh Wh When en en a a a center joined the Registry, they were allowed to include patients up to 6 months retrospectively.
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cardiac disease, cardiac diagnosis, prior interventions, cardiac symptoms, medication and obstetric history. The countries of origin were subdivided in emerging and developed countries according to the International Monetary Fund (IMF) classification 12 .
Maternal mortality was defined as death during pregnancy and up to one week after delivery. Miscarriage was defined as loss of pregnancy up to 24 weeks and fetal mortality as fetal loss beyond 24 weeks. Thrombotic events include valve thrombosis, pulmonary embolism, deep vein thrombosis or any ischemic cardio-or cerebrovascular event. Major bleeding was defined as a hemorrhage resulting in at least a 1 gm/dl (or 0.62 mmol/l) decrease in hemoglobin, need for blood product transfusion, or end-organ damage such as hemorrhagic cerebrovascular accident or retina bleeding. Postpartum hemorrhage was defined as increased blood loss (more than 500 mL after vaginal delivery or more than 1000 mL after caesarean delivery) directly after delivery and up until 24 hours postpartum. Serious adverse events were maternal mortality, fetal loss, thrombotic events, major hemorrhagic events, supraventricular or ventricular arrhythmia requiring treatment, heart failure, endocarditis, acute coronary syndrome, aortic dissection, preeclampsia or HELLP (Hemolysis Elevated Liver enzymes Low Platelets) syndrome. The endpoint live birth was defined as pregnancies resulting in a live neonate.
Further definition of pregnancy outcome is described in the first ROPAC paper 3 .
Data Analysis
We focused on the differences of outcome between women with a MHV and women with
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Clearly, there is no second period of anticoagulation for patients with a pregnancy loss or maternal mortality in the first trimester; consequently these cases were excluded from the analysis of anticoagulation regimes.
Categorical data are presented as frequencies and percentages, and chi-square tests or
Fisher's exact tests are used, as appropriate, to reveal differences between patients independent subgroups. After evaluation of normality by Kolmogorov-Smirnov tests, continuous data are presented as mean ± one standard deviation (SD), or median with first and third quartiles range (Q1-Q3). Student's t and Mann Whitney tests are used, as appropriate, to study differences between two groups. Univariable logistic regression analyses are used to assess associations between subgroups and outcome, followed by multivariable logistic regression to adjust for potential confounders. We adjusted for baseline characteristics that were significantly different between the subgroups. Results are presented as odds ratios (ORs) with 95% confidence interval.
P-values are considered significant if smaller than 0.05 in context of a 2-sided test. The statistical analysis is carried out using IBM SPSS Statistics 21.0 (SPSS Inc., Chicago IL, USA).
Results
Among the 2966 pregnancies enrolled in the Registry there were 212 patients with a MHV, 134
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Pregnancy outcomes
Maternal mortality was higher for MHV (1.4%) than for NoPHV (0.2%, p=0.025), which in itself was much higher than in the non-cardiac pregnant population ( Table 2 ). In patients with a MHV, two of the three deaths were directly prosthetic valve related due to MVT (patients 1 and 2 in Table 3 ) and one to pre-existing poor LV function exacerbated by H1N1 flu at 24 weeks.
THV patients are further described below.
Miscarriage before and fetal death after 24 weeks were both much higher in MHV than in NoPHV patients ( Table 2 ) and the percentage of pregnancies ending with a live mother and child was significantly less with MHV (81.6%) than with NoPHV (97.7%, p<0.001). When all serious adverse events were considered, the chances of an event free pregnancy with a live birth was 58.0% for women with MHV and 78.1% for NoPHV (p<0.001). The assessment of adjusted ORs for the significant different outcomes are presented in Table 2b .
Thrombotic and hemorrhagic events
Thrombotic events were significantly more common with MHV than with NoPHV and this difference was due to the occurrence of the very serious complication of MVT in ten patients (4.7%) ( Table 3 ). There was no significant difference in the occurrence of MVT in mitral mechanical valves (4.4%) versus aortic mechanical valves (2.6%, p=1.00). MVT emerged at all stages of pregnancy and on every possible anticoagulation regime. However, 50% of the MVTs occurred in the first trimester and all these five patients had been switched from VKA to heparin in some form. No MVTs in the first trimester occurred in patients taking VKA. This difference Miscarriage before and fetal death after 24 weeks were both much higher i i in n n MH MH MHV V V th th than an an in NoPHV patients ( Table 2 ) and the percentage of pregnancies ending with a live mother and child d d wa wa was s s si si sign gn g ific ic ica a antly less with MHV (81.6%) th th than an an with NoPHV (97.7% 7% 7%, p<0.001). When all e e eri i ious adverse e e ev ev e en n nts ts ts w w wer er ere e e co co con ns nsid id ide er ered ed ed, th h he e ch h hanc c ces s s of f f a a an n n ev ev even en ent t fr r ree ee ee p p pre r r g gnan n ncy cy cy w w wit it ith h h a a a l li live ve ve b b bir ir irth th th wa wa as 58 5 5 .0% fo fo for w wo w m me m n n n w wi w th M M MHV H H a a and nd n 78. 8 1% % % for N No oPH H HV V V (p (p (p<0 <0 <0.0 0 001 1). ). ). The h he ass ss sses es essmen en ent t t of f a a adjus s ste ed OR OR ORs s s fo fo for r r th th the e e si si sign gn gnif if ific ic ican an ant t t di di diff ff ffer er eren en ent t t o o out t utco co come me mes s s ar ar are e e pr pr pres es esen en ente te ted d d in in in t t t Ta Ta Tabl bl ble e e 2b 2b 2b.
was not statistically significant (MVT in 0% of patients on VKA, versus MVT in 3.6% of patients on some form of heparin, p=0.169).
Bleeding complications were also significantly more common in patients with MHV than with NoPHV (p<0.001), and were mainly around the time of delivery. Hemorrhage did not induce other adverse events such as heart failure, maternal mortality or fetal demise.
Anti-Xa measurements in patients receiving LMWH were performed and reported in 57% of patients receiving LMWH. Most women (60%) had a target level of 1.0 to 1.2 U/ml, versus a minority who had a target level of 0.6-1.0 U/ml or 0.8-1.2 U/ml. The number of measurements varied between 3 and 42 times. The percentage of measurements that were within the target range was 73%. Three patients experienced a mechanical valve thrombosis while having respectively three out of five, four out of five and four out of four anti-Xa measurements within the target range.
Anticoagulation regimes
The anticoagulants and regimes used are summarized in Figure 2 and Figure 3 . Heparin, in some form, was the most commonly used medication in the first trimester. When UFH was used, it was usually given subcutaneously. Most women received VKA from 14-36 weeks and the majority of deliveries were covered with UFH. Only 7 women were on VKA at delivery and 5 of these were delivered by Cesarean Section (CS). Two were delivered vaginally without an adverse event. The main difference between the regimes (Figure 3 ) was that the use of VKA during pregnancy resulted in fewer live births (p=0.026). Figure 4 depicts the association between anticoagulation in the first trimester and fetal mortality. The use of VKA in the first trimester was associated with a higher rate of miscarriage (28.6% versus 9.2% in women receiving heparin, p<0.001) and late fetal death (7.1% versus 0.7%, p=0.016). Rates of he target range was 73%. Three patients experienced a mechanical valve thrombo bo osi si sis s s wh wh whil il ile e e having respectively three out of five, four out of five and four out of four anti-Xa measurements with h hin in in t t the he he t t tar ar arget t t ra a ange. o o ome me me f f for or orm m m, was as as t t the he he m m mos os ost t t co co comm mm mmon on only l ly use se sed d d me me medi di dica ca cati ti tion on on i i in n n th th the e e fi fi firs rs rst t t tr tr trim im imes es este te ter r r. W W Whe he hen n n UF UF UFH H H wa a was s s us s used ed ed, , miscarriage or fetal loss in high versus low dosage VKA ( 5mg warfarin or 2mg acenocoumarol or 3mg phenprocoumon) were not significantly different. Complications and their relation to the anticoagulant therapy used, is presented in Figure 1 in the online supplement.
Aspirin was used in the second and third trimester in only 13 patients in addition to other anticoagulation regimes. There were no patients administered on aspirin as monotherapy. MVT in the second or third trimester did not occur in the 13 patients (0.0%) on aspirin, while five of the 199 patients (2.5%) without aspirin (p=1.00) developed MVT. Hemorrhagic events occurred in eight patients (61.5%) on aspirin and in 41 patients (20.6%) without aspirin (p=0.002).
Congenital abnormalities
Two neonates were diagnosed with congenital heart disease. One child of a woman taking VKA in the first trimester had a combination of atrial septal defect, persistent ductus arteriosus and pulmonary stenosis. The heart defect of the other neonate was not specified. Hydrocephalus occurred in two children (both mothers took VKA in the first trimester). One twin of a mother taking VKA in the first trimester had an unspecified congenital disorder. Taken together, congenital abnormalities were present in 6·8% of the live births of mothers receiving VKA in the first trimester versus 0·8% when they were receiving some form of heparin (p=0·055).
Developed versus emerging countries
There was a clear difference between the anticoagulation regimes used in the different parts of the world, with a preference for the use of UFH in any stage of the pregnancy in emerging countries (Table 4a and 4b) .
Patients with a MHV in developed countries were admitted to the hospital more frequently than patients in emerging countries, also for cardiac reasons. Patients from developed
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Tissue valves
THV. There was no significant difference in maternal mortality. However, the two cases of death in the MHV group were directly prosthesis related, while this was not the case in the THV group:
there was one unexplained out of hospital arrest (ventricular fibrillation) and one death during emergency Caesarean section (CS) performed for fetal rather than for cardiac reasons.
Patients with a MHV had significantly fewer pregnancies resulting in a live mother and child than patients with a THV (81.6% versus 97.0%, p<0.001). The chance of a pregnancy free of serious adverse events was 58.0% for MHV, compared to 79.1% for women with a THV (p<0.001). Overall the risk of complications remained higher for MHV patients, after adjustment for baseline characteristics (Table 5b) .
Discussion
In this large contemporary study of 212 women with a MHV, maternal mortality was 1.4%, pregnancy loss was 18.4%, valve thrombosis occurred in 4.7% of the pregnancies and hemorrhagic complications in 23.1%. Overall, serious complications occurred in over 40% of pregnancies in women with a MHV, which is significantly higher compared to other groups of cardiac patients. Anticoagulation regimes varied widely but none proved to be superior in all here was one unexplained out of hospital arrest (ventricular fibrillation) and one d d dea ea eath th th d d dur ur urin in ing g g emergency Caesarean section (CS) performed for fetal rather than for cardiac reasons.
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Pregnancy outcomes
The maternal mortality rate for women with a MHV in this Registry is 1.4%, a 30 to 200-fold increase when compared to the normal pregnant population (depending on the country from which the normal data were drawn). MVT is the most feared complication and occurred in 4.7%
of pregnancies and was associated with 20% mortality. This is consistent with the current literature, although the mortality and MVT rates vary in previous studies 5, [13] [14] [15] [16] . We found a relatively high percentage of hemorrhagic complications (23%) compared to other studies where rates of hemorrhage varied between 6 and 23% 5, 13, 15, 17 . Fetal loss, on the other hand, occurred in 18.4% of all pregnancies, which is less frequent than expected, varying in literature from 24 to 65% 5, 13-15, 17, 18 . This might reflect the reduction in VKA use in the past few years or that women who lost their child in the first trimester may have been underreported in our study.
Developed versus emerging countries
The outcome of pregnancy in emerging and developed countries was quite comparable, regarding maternal and fetal survival and heart failure events. However, patients in developed countries were more frequently admitted to hospital and had more hemorrhagic complications.
Hospital admission is expensive and rates might be influenced by financial factors and local facilities. The higher rate of hemorrhage was marked, which is just partly explained by the higher Cesarean section rate in developed countries, and may be related to anticoagulant use.
The high frequency of preterm CS is an important observation. The current guidelines 9 suggest that Cesarean sections should be performed only for obstetric reasons, unless a patient is using VKA in the pre-delivery phase. This is relevant for an emergency CS, which, intriguingly, was not performed more frequently in developed countries. e e ega ga gard rd rdin in ing g g ma ma mate te tern rn rnal al al a a and nd nd f f fet et etal al al s s sur r urviv i ival al al a a and nd nd h h hea ea eart rt rt f f fai ai ailu l lure re re e e eve e vent nt nts s s. H H How o owev e ever er er, pa pa pati ti tien en ents ts ts i i in n n de de deve e velo lo lope pe ped d d
Anticoagulation
In the previous literature, heparin, and specifically UFH, was associated with an increased thrombotic risk 5 . Closer examination of our data shows that 50% of the MVTs occurred during the first trimester and that these five patients were being treated with heparin. MVT did not occur in any patients on VKA in the first trimester. Although not statistically significant, these data are striking. In considering the balance of risk between valve thrombosis and hemorrhage, it is clear that MVT was the more serious complication, associated with an increase in both maternal and fetal mortality, whereas hemorrhage was not associated with such serious sequelae.
The risk of miscarriage and late fetal death was clearly increased in women receiving VKA in the first trimester and in those receiving VKA throughout pregnancy. Although we found no difference in miscarriage rates between women receiving low and high dose VKA, there is one promising study showing that fetal loss might be lower in women who require a low VKA dosage to achieve effective anticoagulation 19 . This may be important for women with new generation aortic mechanical valves, with potentially less need for aggressive anticoagulation.
However, more data are clearly warranted.
The current anticoagulant regimes differ considerably; despite this there is no clear evidence in support of one approach over another. The choice is often driven by physician experience and preference and sometimes by economic factors, forcing a choice for the less expensive UFH. Although several regimes have been recommended and advised by different guidelines, our data do not suggest that one regime is definitively superior. Our study is particularly relevant as it reports the current treatments used in 40 different centers across the world. Despite the breadth of the study, it is still not possible to recommend a uniform approach for all patients. Due to the limited numbers of patients treated with aspirin, it is not possible to VKA in the first trimester and in those receiving VKA throughout pregnancy. Alt t tho ho houg ug ugh h h we we we found no difference in miscarriage rates between women receiving low and high dose VKA,
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conclude whether the addition of aspirin is of any benefit. Conversely, it appears that the addition of aspirin to other forms of anticoagulation is associated with an increased risk of hemorrhage. If the risk of MVT or other thromboembolic complications were to be reduced by the addition of aspirin, then the greater risk of hemorrhage may be deemed to be acceptable,
however as yet, there is no evidence of this.
Our results indicate a stark choice between a lower rate of thrombosis but a much higher rate of fetal loss when women remain on VKA in the first trimester, and a probable higher thrombosis rate (including MVT) but less fetal loss if they are switched to heparin for the first trimester. This decision can only be made by the mother with the aid of careful counseling. It is possible that frequent monitoring of peak and trough anti-Xa_ENREF_16 levels or activated partial thromboplastin time will mitigate the risks involved and make the switch to heparin the preferable course. Whichever regime is chosen, it is clear that this is a dangerous situation, which demands that anticoagulant control should be as near to perfect as possible 20, 21 .
Choice of valve type in women of childbearing age
As previously shown, patients with tissue valves experienced less morbidity and less fetal loss than patients with mechanical valves during pregnancy 22, 23 and this should be discussed with women before valve replacement. Currently, the superior durability of a mechanical valve often dominates the discussion 7 , but consideration should be given to a bioprosthetic valve, which would be safer in pregnancy and which could be replaced with a mechanical valve when it fails.
However, if the availability of cardiac surgery is limited, then it may not be possible to offer women two valve replacements. Of course valve repair, when feasible, would be the best option.
Study limitations
This study, as in all registries, provides an insight into the current situation for pregnant women possible that frequent monitoring of peak and trough anti-Xa_ENREF_16 a levels or a a act ct ctiv iv ivat at ated ed ed p p par ar arti t t a hromboplastin time will mitigate the risks involved and make the switch to heparin the pref f fer er erab ab able le le c c cou ou o rse e e. W Whichever regime is chosen, i i it t t is is is clear that this is a da da dang n erous situation, which d d dem m mands that a ant nt ntic coa a agu gu gula la lant nt nt c c con on ont tr trol ol ol s s sho ho hou uld d be b b as n nea a ar t to o o p pe perf rf rfe e ect t t a a as p pos os ssi si sible 20, 21 21 21 .
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A As As pre i i viou l sl sly h sh shown, p t t ati ie ie t t nts i i with th th t t ti is issue val l lves experi ie ienc d ed ed l l less mo b rb rbid id idit it ity and d d l le less f f f t t et l al al l l loss with a mechanical valve. Although it is one of the largest studies, the sample size is still limited.
The prospective nature of this study should prevent from selection bias. However, participation on voluntary basis can always introduce selection bias, which should be kept in mind while interpreting our results.
The outcome of pregnancy in a normal population has been provided to illustrate differences; however, as the percentages vary widely throughout the world, extrapolation needs to be done with caution. In addition, the relative contribution of individual countries to this Registry needs to be considered, however, the numbers of patients from different countries are too low for statistical analysis. Despite this, we have been able to show differences between emerging and developed countries in this and in a previous publication 3 . We aim to provide a global perspective, which, with local studies, will be invaluable in the development of future guidelines.
Conclusions
Patients with a MHV are at increased risk of maternal and fetal mortality and morbidity, particularly thrombotic and hemorrhagic complications during pregnancy. Half of the MVTs occurred in the first trimester and all of these on some form of heparin, while the use of VKA was associated with miscarriage and fetal death. Current anticoagulation regimes differ widely and, when considering both the outcome for both mother and fetus, none is clearly superior. The outcome of pregnancy in patients with a tissue valve is less hazardous, especially for the fetus.
Women with a MHV should be counseled about the potential consequences of pregnancy and receive extensive guidance and care throughout pregnancy, delivery and the postpartum period, from a specialized multidisciplinary team.
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Perspectives
Competency in Patient Care
The impressive rates of complications during pregnancies in women with MHV urges the need for centralization of care, as is already implemented for instance for patients with complex congenital heart disease. Optimal counseling and detailed anticoagulation fine-tuning in a specialized center may improve outcome.
Translational Outlook
Clearly the best way of discovering the optimal management for patients with a mechanical valve prosthesis during pregnancy would be a randomized controlled trial. However, this is not feasible and therefore a large prospective observational study is the best option in which the outcomes of the different anticoagulant regimes can be compared. This can highlight periods of greatest risk and identify approaches that minimize these risks. usted for baseline characteristics: maternal age, nulliparity, hypertension prior to pregnancy, signs of heart failure and atrial fibrillation; since there we for miscarriage this OR was adjusted for nulliparity, signs of heart failure and atrial fibrillation e to l lim im mit it ited ed ed n n num um umbe be ber r r of eve v v nt nt n s, no adjusted OR could be determined *adjusted for baseline characteristics: maternal age, nulliparity, signs of heart failure and atrial fibrillation; since there were 35 cases for miscarriage this OR was adjusted for nulliparity, signs of heart failure and atrial fibrillation **due to limited number of events, no adjusted OR could be determined to limited number of events, no adjusted OR could be determined VKA=Vitamin K Antagonist. UFH=Unfractionated Heparin. LMWH=Low Mole e ecu cu cula la lar r r We We Weig ig ight ht ht
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